Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.from http://www.kereos.com/
Publications 1 show all
- 1Angiogenesis Inhibitors/therapeutic use
- 1Nanoparticles/therapeutic use
- 1Neoplasms, Experimental/drug therapy
- 1Neovascularization, Pathologic/drug therapy
- 1Prodrugs/therapeutic use
- 1Taxoids/therapeutic use
Patents 68show all
- 42A61K - Preparations for medical, dental, or toilet purposes
- 15B82Y - Specific uses or applications of nanostructures
- 13G01N - Investigating or analysing materials by determining their chemical or physical properties
- 5B01D - Separation
- 4C07D - Heterocyclic compounds
- 4C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
- 2C07K - Peptides
- 2C12N - Microorganisms or enzymes
- 2C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
SEC Filings show all
Crunchbase Investment Rounds
|Date||Amount||Round||Valuation||Lead Investor||Other Investors|
|2005-09-20||$19,500,000||Series B||Charter Life Sciences||180 Degree Capital, Apjohn ventures, Alafi Capital, Lux Capital, Genentech, MB Venture Partners, Orchard Venture Partners, Triathlon Medical Venture Partners, RiverVest, Koninklijke Philips, Barnes-Jewish Hospital, Prolog Ventures|
SEC Form D Funding Events
- Stephen Snowdy, Ph.D.
- Phillip M Buckler
- John M Rice, Ph.D.
- Gregory R Johnson, Ph.D.
- Fred Schwartzer
- Michael Loberg, Ph.D.
- Samuel Wickline, M.D.
- Phillip M. Buckler
- Gregory R. Johnson, Ph.D.
- John Rice, Ph.D.
- Fred Schwarzer
- Stephen Snowdy
- Samuel A. Wickline, M.D.
- Gregory R. Johnson, Ph. D.
- Michael D. Loberg, Ph. D.
- John Rice, Ph. D.
- Fred A. Schwarzer, J.D.
- Gary Stevenson